Role of the Ketogenic Diet in Psychiatry: Review of Clinical Trials and Case Studies
DOI:
https://doi.org/10.12775/QS.2025.41.60265Keywords
ketogenic diet, mental health, psychiatry, mood disorders, bipolar disorder, depression, schizophrenia, neurodegenerative disease, Parkinson's disease, Alzheimer's diseaseAbstract
The ketogenic diet (KD) has gained a lot of recognition as a treatment in refractory epilepsy. Due to its success, more and more researchers have begun to question whether this diet would have a similar positive influence on patients suffering from various psychiatric disorders. This paper explores the use of the ketogenic diet in psychiatric conditions, particularly in mood disorders, schizophrenia, and neurodegenerative diseases. The initial studies have a rather promising outcome, but more evidence needs to be gathered in order to ensure this diet is a safe and credible tool in managing psychiatric symptoms. This review discusses current studies, challenges, and future research directions.
References
1. Sampaio LP. Ketogenic diet for epilepsy treatment. Arq Neuropsiquiatr. 2016 Oct;74(10):842-848. doi: 10.1590/0004-282X20160116. PMID: 27759811.
2. Sethi S, Wakeham D, Ketter T, Hooshmand F, Bjornstad J, Richards B, Westman E, Krauss RM, Saslow L. Ketogenic Diet Intervention on Metabolic and Psychiatric Health in Bipolar and Schizophrenia: A Pilot Trial. Psychiatry Res. 2024 May;335:115866. doi: 10.1016/j.psychres.2024.115866. Epub 2024 Mar 20. PMID: 38547601.
3. Ułamek-Kozioł M, Czuczwar SJ, Januszewski S, Pluta R. Ketogenic Diet and Epilepsy. Nutrients. 2019 Oct 18;11(10):2510. doi: 10.3390/nu11102510. PMID: 31635247; PMCID: PMC6836058.
4. Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, Bäckers L, Rothe P, Cipriani A, Davis J, Salanti G, Leucht S. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019 Sep 14;394(10202):939-951. doi: 10.1016/S0140-6736(19)31135-3. Epub 2019 Jul 11. Erratum in: Lancet. 2019 Sep 14;394(10202):918. doi: 10.1016/S0140-6736(19)31677-0. PMID: 31303314; PMCID: PMC6891890.
5. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018 Apr 7;391(10128):1357-1366. doi: 10.1016/S0140-6736(17)32802-7. Epub 2018 Feb 21. PMID: 29477251; PMCID: PMC5889788.
6. Campos AI, Mulcahy A, Thorp JG, Wray NR, Byrne EM, Lind PA, Medland SE, Martin NG, Hickie IB, Rentería ME. Understanding genetic risk factors for common side effects of antidepressant medications. Commun Med (Lond). 2021 Nov 9;1:45. doi: 10.1038/s43856-021-00046-8. PMID: 35602235; PMCID: PMC9053224.
7. Iversen TSJ, Steen NE, Dieset I, Hope S, Mørch R, Gardsjord ES, Jørgensen KN, Melle I, Andreassen OA, Molden E, Jönsson EG. Side effect burden of antipsychotic drugs in real life - Impact of gender and polypharmacy. Prog Neuropsychopharmacol Biol Psychiatry. 2018 Mar 2;82:263-271. doi: 10.1016/j.pnpbp.2017.11.004. Epub 2017 Nov 7. PMID: 29122637.
8. Solmi M, Fornaro M, Ostinelli EG, Zangani C, Croatto G, Monaco F, Krinitski D, Fusar-Poli P, Correll CU. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry. 2020 Jun;19(2):214-232. doi: 10.1002/wps.20765. PMID: 32394557; PMCID: PMC7215080.
9. Tandon R, Lenderking WR, Weiss C, Shalhoub H, Barbosa CD, Chen J, Greene M, Meehan SR, Duvold LB, Arango C, Agid O, Castle D. The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey. Ann Gen Psychiatry. 2020 Jul 13;19:42. doi: 10.1186/s12991-020-00292-5. Erratum in: Ann Gen Psychiatry. 2020 Aug 10;19:45. doi: 10.1186/s12991-020-00294-3. PMID: 32684942; PMCID: PMC7359579.
10. Nelson JC, Spyker DA. Morbidity and Mortality Associated With Medications Used in the Treatment of Depression: An Analysis of Cases Reported to U.S. Poison Control Centers, 2000-2014. Am J Psychiatry. 2017 May 1;174(5):438-450. doi: 10.1176/appi.ajp.2016.16050523. Epub 2017 Jan 31. PMID: 28135844.
11. Novak L, Svab V. Antipsychotics side effects' influence on stigma of mental illness: focus group study results. Psychiatr Danub. 2009 Mar;21(1):99-102. PMID: 19270631.
12. Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014 Jun 23;5:43-62. doi: 10.2147/PROM.S42735. PMID: 25061342; PMCID: PMC4085309.
13. Chmiel I. Ketogenic diet in therapy of bipolar affective disorder - case report and literature review. Psychiatr Pol. 2022 Dec 31;56(6):1345-1363. English, Polish. doi: 10.12740/PP/OnlineFirst/136356. Epub 2022 Dec 31. PMID: 37098202.
14. Calabrese L, Frase R, Ghaloo M. Complete remission of depression and anxiety using a ketogenic diet: case series. Front Nutr. 2024 May 14;11:1396685. doi: 10.3389/fnut.2024.1396685. PMID: 38887496; PMCID: PMC11182043.
15. Kraft BD, Westman EC. Schizophrenia, gluten, and low-carbohydrate, ketogenic diets: a case report and review of the literature. Nutr Metab (Lond). 2009 Feb 26;6:10. doi: 10.1186/1743-7075-6-10. PMID: 19245705; PMCID: PMC2652467.
16. Palmer CM, Gilbert-Jaramillo J, Westman EC. The ketogenic diet and remission of psychotic symptoms in schizophrenia: Two case studies. Schizophr Res. 2019 Jun;208:439-440. doi: 10.1016/j.schres.2019.03.019. Epub 2019 Apr 6. PMID: 30962118.
17. Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg GD, McCarten JR, Malphurs J, Prieto S, Chen P, Loreck DJ, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL, Vidal-Cardona A, Arroyo LM, Cruz AR, Zachariah S, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL, Woodman C, Monnell KA, Gordon K, Tomaska J, Segal Y, Peduzzi PN, Guarino PD. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014 Jan 1;311(1):33-44. doi: 10.1001/jama.2013.282834. Erratum in: JAMA. 2014 Mar 19;311(11):1161. PMID: 24381967; PMCID: PMC4109898.
18. Siemers E, Holdridge KC, Sundell KL, Liu-Seifert H. Function and clinical meaningfulness of treatments for mild Alzheimer's disease. Alzheimers Dement (Amst). 2016 Mar 10;2:105-12. doi: 10.1016/j.dadm.2016.02.006. PMID: 27239541; PMCID: PMC4879645.
19. Meeuwsen EJ, Melis RJ, Van Der Aa GC, Golüke-Willemse GA, De Leest BJ, Van Raak FH, Schölzel-Dorenbos CJ, Verheijen DC, Verhey FR, Visser MC, Wolfs CA, Adang EM, Olde Rikkert MG. Effectiveness of dementia follow-up care by memory clinics or general practitioners: randomised controlled trial. BMJ. 2012 May 15;344:e3086. doi: 10.1136/bmj.e3086. PMID: 22589500; PMCID: PMC3352696.
20. Phillips MCL, Deprez LM, Mortimer GMN, Murtagh DKJ, McCoy S, Mylchreest R, Gilbertson LJ, Clark KM, Simpson PV, McManus EJ, Oh JE, Yadavaraj S, King VM, Pillai A, Romero-Ferrando B, Brinkhuis M, Copeland BM, Samad S, Liao S, Schepel JAC. Randomized crossover trial of a modified ketogenic diet in Alzheimer's disease. Alzheimers Res Ther. 2021 Feb 23;13(1):51. doi: 10.1186/s13195-021-00783-x. PMID: 33622392; PMCID: PMC7901512.
21. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N; Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15;23(15):2129-70. doi: 10.1002/mds.22340. PMID: 19025984.
22. Phillips MCL, Murtagh DKJ, Gilbertson LJ, Asztely FJS, Lynch CDP. Low-fat versus ketogenic diet in Parkinson's disease: A pilot randomized controlled trial. Mov Disord. 2018 Aug;33(8):1306-1314. doi: 10.1002/mds.27390. Epub 2018 Aug 11. Erratum in: Mov Disord. 2019 Jan;34(1):157. doi: 10.1002/mds.27596. PMID: 30098269; PMCID: PMC6175383.
23. Zhu H, Bi D, Zhang Y, Kong C, Du J, Wu X, Wei Q, Qin H. Ketogenic diet for human diseases: the underlying mechanisms and potential for clinical implementations. Signal Transduct Target Ther. 2022 Jan 17;7(1):11. doi: 10.1038/s41392-021-00831-w. PMID: 35034957; PMCID: PMC8761750.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Magda Minkiewicz, Dominika Musialska, Michał Bolek, Monika Fidyk, Bartosz Jagieła, Aleksandra Kędzia
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 112
Number of citations: 0
